Divis Lab USFDA
The US health regulator has issued a warning letter to the Drug firm Divis Laboratories at Visakhapatnam. However, the company along with few external consultants and subject matter experts are trying to work to address the concerns of the United States Food and Drug Administration (USFDA) and is striving to fully meet the compliance requirements. The company has reportedly not provided the details of the warning letter.
The company said that the laboratories have responded to the USFDA inspection observations with a very appropriate remediation process to overcome the deficiencies which have been observed.
Earlier, when an import alert has been issued the regulator had exempted several products which are being manufactured at the Unit II in Visakhapatnam, said the Divis Laboratories. The exempted products include Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium and BOC core succinate.
However, the company will respond to this warning letter from the USFDA with a detailed plan within the stipulated time. It is also said that earlier, in a regulatory filing the regulator had issued import alert for products which are being made at Visakhapatnam unit citing violation of products made at Visakhapatnam unit citing violation of manufacturing norms and refusal of inspection.
Girls in the age group of 9-14 years were administered HPV booster vaccine dose at…
There's always something happening in the sports field around the world. Like, currently, the FIFA…
The first convocation of JNTU-GV was held at AU Convocation Hall in Visakhapatnam on Saturday.…
Sricharan, husband of Vizag techie Radha Gayatri who died under mysterious conditions in Mussoorie last…
Warship INS Mahendragiri, a Nilgiri-class stealth guided missile frigate of the Indian Navy, was commissioned…
The State Cabinet, at its meeting on Friday, approved the establishment of a National Investigation…